Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Takeru Ito, Yoshiyuki Kubo, Yuma Tega, Shin-Ichi Akanuma, Ken-Ichi Hosoya
Ribavirin, an antiretroviral agent targeting the hepatitis C virus, causes male reproductive toxicity. This study investigated the mechanism of ribavirin transport at the blood-testis barrier (BTB). In vivo mouse integration plot analysis after intravenous administration revealed that the net influx clearance of [3 H]ribavirin in the testis was 3.6-fold greater than that of [14 C]D-mannitol, a paracellular transport marker, implying transcellular transport of ribavirin across the BTB. Moreover, [3 H]ribavirin uptake by TM4 cells, mouse-derived Sertoli cells, was time- and concentration-dependent, with a Km value of 2...
April 26, 2024: Journal of Pharmaceutical Sciences
#22
REVIEW
Adam J Gehring, Loghman Salimzadeh
With the increasing momentum and success of monoclonal antibody therapy in conventional medical practices, there is a revived emphasis on the development of monoclonal antibodies targeting the hepatitis B surface antigen (anti-HBs) for the treatment of chronic hepatitis B (HBV) and hepatitis D (HDV). Combination therapies of anti-HBs monoclonal antibodies, and novel anti-HBV compounds and immunomodulatory drugs presenting a promising avenue to enhanced therapeutic outcomes in HBV/HDV cure regimens. In this review, we will cover the role of antibodies in the protection and clearance of HBV infection, the association of anti-HBV surface antigen antibodies (anti-HBs) in protection against HBV and how antibody effector functions, beyond neutralization, are likely necessary...
April 26, 2024: Antiviral Research
#23
JOURNAL ARTICLE
Sha Zhang, Ying-Feng Gao, Kai Zhang, Guo-Rong Deng, Guang-Xiang He, Ping-Ping Gao, Yi-Kang Yu, Yuan Yuan, Shu-Juan Xing, Na Zhao, Hong Zhang, Yong-Chang Di-Wu, Yi-Han Liu, Bing-Dong Sui, Zhe Li, Jing Ma, Chen-Xi Zheng
Non-alcoholic fatty liver disease (NAFLD), a chronic liver condition and metabolic disorder, has emerged as a significant health issue worldwide. D-mannose, a natural monosaccharide widely existing in plants and animals, has demonstrated metabolic regulatory properties. However, the effect and mechanism by which D-mannose may counteract NAFLD have not been studied. In this study, network pharmacology followed by molecular docking analysis was utilized to identify potential targets of mannose against NAFLD, and the leptin receptor-deficient, genetically obese db/db mice was employed as an animal model of NAFLD to validate the regulation of D-mannose on core targets...
April 24, 2024: Biochemical and Biophysical Research Communications
#24
JOURNAL ARTICLE
Le Zhang, Mortada El-Shabrawi, Louise A Baur, Christopher D Byrne, Giovanni Targher, Mohit Kehar, Gilda Porta, Way Seah Lee, Sander Lefere, Serap Turan, Anna Alisi, Ram Weiss, Maria Felicia Faienza, Ambika Ashraf, Shikha S Sundaram, Anshu Srivastava, Ruth De Bruyne, Yunkoo Kang, Flora Bacopoulou, Yong-Hai Zhou, Andy Darma, Monica Lupsor-Platon, Masahide Hamaguchi, Anoop Misra, Nahum Méndez-Sánchez, Nicholas Beng Hui Ng, Claude Marcus, Amanda E Staiano, Nadia Waheed, Saleh A Alqahtani, Cosimo Giannini, Ponsiano Ocama, Mindie H Nguyen, Maria Teresa Arias-Loste, Mohamed Rabea Ahmed, Giada Sebastiani, Yong Poovorawan, Mamun Al Mahtab, Juan M Pericàs, Themis Reverbel da Silveira, Peter Hegyi, Amer Azaz, Hasan M Isa, Chatmanee Lertudomphonwanit, Mona Issa Farrag, Ahmed Abd Alwahab Nugud, Hong-Wei Du, Ke-Min Qi, Nezha Mouane, Xin-Ran Cheng, Tawfiq Al Lawati, Eleonora D T Fagundes, Hasmik Ghazinyan, Adamos Hadjipanayis, Jian-Gao Fan, Nicoleta Gimiga, Naglaa M Kamal, Gabriela Ștefănescu, Li Hong, Smaranda Diaconescu, Ming Li, Jacob George, Ming-Hua Zheng
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in children and adolescents, particularly those with obesity. NAFLD is considered a hepatic manifestation of the metabolic syndrome due to its close associations with abdominal obesity, insulin resistance, and atherogenic dyslipidemia. Experts have proposed an alternative terminology, metabolic dysfunction-associated fatty liver disease (MAFLD), to better reflect its pathophysiology. This study aimed to develop consensus statements and recommendations for pediatric MAFLD through collaboration among international experts...
April 24, 2024: Med
#25
JOURNAL ARTICLE
Charlotte Hateley, Antoni Olona, Laura Halliday, Matthew L Edin, Jeong-Hun Ko, Roberta Forlano, Ximena Terra, Fred B Lih, Raúl Beltrán-Debón, Penelopi Manousou, Sanjay Purkayastha, Krishna Moorthy, Mark R Thursz, Guodong Zhang, Robert D Goldin, Darryl C Zeldin, Enrico Petretto, Jacques Behmoaras
BACKGROUND: Obesity drives maladaptive changes in the white adipose tissue (WAT) which can progressively cause insulin resistance, type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated liver disease (MASLD). Obesity-mediated loss of WAT homeostasis can trigger liver steatosis through dysregulated lipid pathways such as those related to polyunsaturated fatty acid (PUFA)-derived oxylipins. However, the exact relationship between oxylipins and metabolic syndrome remains elusive and cross-tissue dynamics of oxylipins are ill-defined...
April 26, 2024: EBioMedicine
#26
JOURNAL ARTICLE
Dylan M Johnson, Nittaya Khakhum, Min Wang, Nikole L Warner, Jenny D Jokinen, Jason E Comer, Igor S Lukashevich
Lymphocytic choriomeningitis virus (LCMV) and Lassa virus (LASV) share many genetic and biological features including subtle differences between pathogenic and apathogenic strains. Despite remarkable genetic similarity, the viscerotropic WE strain of LCMV causes a fatal LASV fever-like hepatitis in non-human primates (NHPs) while the mouse-adapted Armstrong (ARM) strain of LCMV is deeply attenuated in NHPs and can vaccinate against LCMV-WE challenge. Here, we demonstrate that internalization of WE is more sensitive to the depletion of membrane cholesterol than ARM infection while ARM infection is more reliant on endosomal acidification...
April 19, 2024: Viruses
#27
JOURNAL ARTICLE
Beatrice Zovich, Catherine Freeland, Holly Moore, Kara Sapp, Anousha Qureshi, Rachel Holbert, Jason Zambrano, Daljinder Bhangoo, Chari Cohen, Richard W Hass, Amy Jessop
The prevalence of hepatitis B and delta viruses (HBV/HDV) among people who use drugs (PWUD) remains largely unknown. In the context of one Philadelphia-based harm reduction organization (HRO), this study aimed to assess HBV/HDV prevalence and facilitate linkage to care. Participants completed a demographic HBV/HDV risk factor survey and were screened for HBV and reflexively for HDV if positive for HBV surface antigen or isolated core antibody. Fisher's exact tests and regression were used to understand relationships between risks and HBV blood markers...
April 18, 2024: Viruses
#28
JOURNAL ARTICLE
Matthieu Blanchet, Léna Angelo, Yasmine Tétreault, Marwa Khabir, Camille Sureau, Andrew Vaillant, Patrick Labonté
Individuals chronically infected with hepatitis B virus (HBV) and hepatitis Delta virus (HDV) present an increased risk of developing cirrhosis and hepatocellular carcinoma in comparison to HBV mono-infected individuals. Although HDV only replicates in individuals coinfected or superinfected with HBV, there is currently no in vitro model that can stably express both viruses simultaneously, mimicking the chronic infections seen in HBV/HDV patients. Here, we present the HepG2BD cell line as a novel in vitro culture system for long-term replication of HBV and HDV...
March 29, 2024: Viruses
#29
REVIEW
Maria Mironova, Marc G Ghany
Hepatitis B virus is a substantial contributor to cirrhosis and hepatocellular carcinoma (HCC) globally. Vaccination is the most effective method for prevention of hepatitis B and its associated morbidity and mortality, and the only method to prevent infection with hepatitis D virus. The hepatitis B vaccine has been used worldwide for more than four decades; it is available in a single- or triple-antigen form and in combination with vaccines against other infections. Introduction of the vaccine and administration at birth led to sustained decline in mother-to-child transmission, chronic hepatitis B, and HCC, however, global birth dose coverage remains suboptimal...
April 18, 2024: Vaccines
#30
REVIEW
Shuzhen Ran, Rui Peng, Qingwan Guo, Jinshuai Cui, Gang Chen, Ziying Wang
The incidence of depression has been steadily rising in recent years, making it one of the most prevalent mental illnesses. As the pursuit of novel antidepressant drugs captivates the pharmaceutical field, the therapeutic efficacy of Traditional Chinese Medicine (TCM) has been widely explored. Chaihu ( Bupleurum ) has been traditionally used for liver conditions such as hepatitis, liver inflammation, liver fibrosis, and liver cancer. It is believed to have hepatoprotective effects, promoting liver cell regeneration and protecting against liver damage...
April 16, 2024: Pharmaceuticals
#31
JOURNAL ARTICLE
Patrycja Wieczorek, Piotr Czekaj, Mateusz Król, Edyta Bogunia, Mateusz Hermyt, Emanuel Kolanko, Jakub Toczek, Aleksandra Skubis-Sikora, Aniela Grajoszek, Rafał Stojko
The route of administration of implanted cells may affect the outcome of cell therapy by directing cell migration to the damaged site. However, the question of the relationship between the route of administration, the efficacy of colonisation of a given organ, and the efficacy of cell therapy has not been resolved. The aim of the study was to localise transplanted intravenously and intraperitoneally human amniotic epithelial cells (hAECs) in the tissues of mice, both healthy and injured, in an animal experimental model of acute liver failure (ALF)...
April 8, 2024: Pharmaceuticals
#32
REVIEW
Lixuan Qian, Jessica L Beers, Klarissa D Jackson, Zhu Zhou
Cannabinoid use has surged in the past decade, with a growing interest in expanding cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) applications into special populations. Consequently, the increased use of CBD and THC raises the risk of drug-drug interactions (DDIs). Nevertheless, DDIs for cannabinoids, especially in special populations, remain inadequately investigated. While some clinical trials have explored DDIs between therapeutic drugs like antiepileptic drugs and CBD/THC, more potential interactions remain to be examined...
April 1, 2024: Pharmaceutics
#33
JOURNAL ARTICLE
Antiviral Effect of Antimicrobial Peptoid TM9 and Murine Model of Respiratory Coronavirus Infection.
Maxim Lebedev, Aaron B Benjamin, Sathish Kumar, Natalia Molchanova, Jennifer S Lin, Kent J Koster, Julian L Leibowitz, Annelise E Barron, Jeffrey D Cirillo
New antiviral agents are essential to improving treatment and control of SARS-CoV-2 infections that can lead to the disease COVID-19. Antimicrobial peptoids are sequence-specific oligo- N -substituted glycine peptidomimetics that emulate the structure and function of natural antimicrobial peptides but are resistant to proteases. We demonstrate antiviral activity of a new peptoid (TM9) against the coronavirus, murine hepatitis virus (MHV), as a closely related model for the structure and antiviral susceptibility profile of SARS-CoV-2...
March 27, 2024: Pharmaceutics
#34
JOURNAL ARTICLE
Praneet Veerapaneni, Brandee Goo, Samah Ahmadieh, Hong Shi, David S Kim, Mourad Ogbi, Stephen Cave, Ronnie Chouhaita, Nicole Cyriac, David J Fulton, Alexander D Verin, Weiqin Chen, Yun Lei, Xin-Yun Lu, Ha Won Kim, Neal L Weintraub
Histone deacetylase (HDAC) 9 is a negative regulator of adipogenic differentiation, which is required for maintenance of healthy adipose tissues. We reported that HDAC9 expression is upregulated in adipose tissues during obesity, in conjunction with impaired adipogenic differentiation, adipocyte hypertrophy, insulin resistance, and hepatic steatosis, all of which were alleviated by global genetic deletion of Hdac9 . Here, we developed a novel transgenic (TG) mouse model to test whether overexpression of Hdac9 is sufficient to induce adipocyte hypertrophy, insulin resistance, and hepatic steatosis in the absence of obesity...
April 18, 2024: Biomolecules
#35
JOURNAL ARTICLE
Xiaxia Du, Yinuo Wang, Felix Kwame Amevor, Zifan Ning, Xun Deng, Youhao Wu, Shuo Wei, Xueqing Cao, Dan Xu, Yaofu Tian, Lin Ye, Gang Shu, Xiaoling Zhao
The aim of this study was to evaluate the effects of a high-energy low-protein (HELP) diet on lipid metabolism and inflammation in the liver and abdominal adipose tissue (AAT) of laying hens. A total of 200 Roman laying hens (120 days old) were randomly divided into two experimental groups: negative control group (NC group) and HELP group, with 100 hens per group. The chickens in the NC group were fed with a basic diet, whereas those in the HELP group were given a HELP diet. Blood, liver, and AAT samples were collected from 20 chickens per group at each experimental time point (30, 60, and 90 d)...
April 17, 2024: Animals: An Open Access Journal From MDPI
#36
JOURNAL ARTICLE
Marcello Dallio, Mario Romeo, Marina Cipullo, Lorenzo Ventriglia, Flavia Scognamiglio, Paolo Vaia, Giorgia Iadanza, Annachiara Coppola, Alessandro Federico
Biological antioxidant potential (BAP) and Reactive Oxygen Metabolites (dROMs) are two tests complementarily assessing systemic oxidative statuses (SOSs) that are never applied in chronic liver disorders (CLDs). We enrolled 41 ursodeoxycholic acid (UDCA)-naïve Primary Biliary Cholangitis (PBC) patients [age: 58.61 ± 11.26 years; females (F): 39], 40 patients with metabolic-dysfunction-associated steatotic livers (age: 54.30 ± 11.21; F: 20), 52 patients with HBV (age: 52.40 ± 8.22; F: 34), 50 patients with (age: 56...
March 23, 2024: Antioxidants (Basel, Switzerland)
#37
JOURNAL ARTICLE
Vaishali Gupta, Chris Major Ncho, Akshat Goel, Chae-Mi Jeong, Yang-Ho Choi
The broiler industry is adversely affected by the rise in global temperature. This study investigated the effects of in ovo feeding of α-ketoglutaric acid (AKG) on growth performance, organ weight, plasma metabolite, plasma oxidative stress, rectal temperature (RT), and hepatic mRNA expression of antioxidant-related genes in Arbor Acres broilers subjected to cyclic heat stress (HS). Three hundred fifty fertile eggs during incubation were divided into 5 groups according to AKG concentrations and temperature conditions...
April 9, 2024: Poultry Science
#38
JOURNAL ARTICLE
Catharina Gerhards, Andreas Teufel, Marlis Gerigk, Michael French, Christoph Antoni, Matthias Ebert, Michael Neumaier, Osman Evliyaoglu
BACKGROUND: To study the relationship of Vitamin D with innate and adaptive immune response parameters in chronic hepatitis B and C patients. METHODS: The laboratory data between January 1, 2013 and February 1, 2023, for patients with chronic hepatitis B (CHB), and chronic hepatitis C (CHC) were extracted. Serum 25-hydroxyl vitamin D, hepatitis B virus serological markers, complements, and subsets of T lymphocytes were determined. Study cohorts were divided into groups based on serum 25-hydroxyl vitamin D levels with further evaluation of laboratory data...
March 30, 2024: Nutrition
#39
JOURNAL ARTICLE
Leonida Hehl, Kate T Creasy, Cecilia Vitali, Eleonora Scorletti, Katharina S Seeling, Mara S Vell, Miriam D Rendel, Donna Conlon, Marijana Vujkovic, Inuk Zandvakili, Christian Trautwein, Kai M Schneider, Daniel J Rader, Carolin V Schneider
BACKGROUND: Common variants of the max-like protein X (MLX)-interacting protein-like (MLXIPL) gene, encoding the transcription factor carbohydrate-responsive element-binding protein, have been shown to be associated with plasma triglyceride levels. However, the role of these variants in steatotic liver disease (SLD) is unclear. METHODS: We used a genome-first approach to analyze a variety of metabolic phenotypes and clinical outcomes associated with a common missense variant in MLXIPL, Gln241His, in 2 large biobanks: the UK Biobank and the Penn Medicine Biobank...
May 1, 2024: Hepatology Communications
#40
JOURNAL ARTICLE
George S Gherlan, Stefan D Lazar, Augustina Culinescu, Dana Smadu, Andreea R Vatafu, Corneliu P Popescu, Simin A Florescu, Emanoil Ceausu, Petre I Calistru
Pegylated interferon alpha 2a continues to be used for the treatment of chronic hepatitis D. The reported on-treatment virologic response varies between 17 and 47%, with relapses in more than 50% of these patients. No stopping rules have been defined, and the duration of the treatment is not clearly established, but it should be between 48 and 96 weeks. In total, 76 patients with compensated liver disease treated with peg-interferon according to the Romanian National protocol for the treatment of hepatitis D were retrospectively included...
March 30, 2024: Tropical Medicine and Infectious Disease
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
